Verflixt! Es sieht so aus, als wenn Sie einen veralteten Browser benutzen. Wir empfehlen Ihnen dringend Ihren Browser zu aktualisieren.
Weitere Informationen über Browser und Updates finden Sie hier

BTG International Ltd

BTG plc is a growing international specialist healthcare company
with a mission to bring to market medical products that meet the
needs of specialist healthcare physicians and their patients.

Our key corporate goals are to drive growth in our existing commercial
business, acquire new products targeting specialist physicians and
progress our development programmes to build future value.

We are focused in three business areas: Specialty Pharmaceuticals,
Interventional Medicine and Licensing & Biotechnology. We develop
our own products, and we in-license or acquire them from others.
We sell direct to customers in the US, and elsewhere principally
through distribution partners.

In everything we do, we are guided by our core values and our code
of conduct. We believe that by doing the right thing every time, we
will deliver enduring value to all our stakeholders.

Key Facts:
  • Diversified revenue from product sales and royalties
  • Products sold directly in the US; through distribution partners elsewhere
  • Development programmes targeting varicose veins and cancer
  • Partnered programmes targeting major indications
  • ~550 employees in Europe, North America, and Australia
  • LSE listed (“BTG”), FTSE 250 constituent; market cap £1,200m (August 2012)
  • Revenue of £197.0m for the year ended 31 March 2012


BTG International Ltd

Fleet Place 5
EC4M 7RD London
Klinische Forschung
Sonstige Tätigkeitsfelder
mehr als 500